[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"GL Pharm Tech Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100658997","phase-3-the-purpose-of-this-study-is-to-evaluate-the-efficacy-and-safety-of-w2505-100658997",false,"NCT07859202","The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.","A Prospective, Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of W2505","Inclusion Criteria:\n\n* Male aged 19 years or older.\n* Capable of completing study diaries and questionnaires independently.\n* Signed written informed consent.\n* run-in medication compliance ≥ 70%\n\nExclusion Criteria:\n\n* Primary hypoactive sexual desire.\n* Erectile dysfunction caused by premature ejaculation or untreated endocrine disorders (e.g., untreated hypogonadism, hyperprolactinemia).\n* Other exclusions applied.","MALE","19 Years",{"count":19,"type":20},228,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of W2505.",[26],"Erectile Dysfunctions","NOT_YET_RECRUITING","2026-09-29",{"date":30,"type":31},"2026-10-05","ACTUAL",{"date":33,"type":20},"2026-09",{"date":35,"type":20},"2027-07",{"name":37,"class":38},"GL Pharm Tech Corporation","INDUSTRY",""]